Milk thistle in liver diseases: past, present, future
Top Cited Papers
- 7 June 2010
- journal article
- review article
- Published by Wiley in Phytotherapy Research
- Vol. 24 (10), 1423-1432
- https://doi.org/10.1002/ptr.3207
Abstract
Silybum marianum or milk thistle (MT) is the most well‐researched plant in the treatment of liver disease. The active complex of MT is a lipophilic extract from the seeds of the plant and is composed of three isomer flavonolignans (silybin, silydianin, and silychristin) collectively known as silymarin. Silybin is a component with the greatest degree of biological activity and makes up 50% to 70% of silymarin. Silymarin is found in the entire plant but it is concentrated in the fruit and seeds. Silymarin acts as an antioxidant by reducing free radical production and lipid peroxidation, has antifibrotic activity and may act as a toxin blockade agent by inhibiting binding of toxins to the hepatocyte cell membrane receptors. In animals, silymarin reduces liver injury caused by acetaminophen, carbon tetrachloride, radiation, iron overload, phenylhydrazine, alcohol, cold ischaemia and Amanita phalloides. Silymarin has been used to treat alcoholic liver disease, acute and chronic viral hepatitis and toxin‐induced liver diseases. Copyright © 2010 John Wiley & Sons, Ltd.Keywords
This publication has 53 references indexed in Scilit:
- A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitisPhytomedicine, 2009
- Oxidative and Nitrosative Stress and Fibrogenic ResponseClinics in Liver Disease, 2008
- In vitroscreening for the tumoricidal properties of international medicinal herbsPhytotherapy Research, 2008
- Multitargeted therapy of cancer by silymarinCancer Letters, 2008
- Interrelation between the inhibition of glycolytic flux by silibinin and the lowering of mitochondrial ROS production in perifused rat hepatocytesLife Sciences, 2008
- A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observationsGut, 2006
- Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen α1(I) and TIMP-1Journal of Hepatology, 2001
- Nuclear Factor Kappa B: Important Transcription Factor and Therapeutic TargetThe Journal of Clinical Pharmacology, 1998
- Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cellsLife Sciences, 1996
- Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liverJournal of Hepatology, 1989